CAR-T cell therapy is the most promising and remarkable treatment in the areas of oncology. It is a treatment that uses cells from a person’s own immune system to fight against cancer. CAR-T Cell therapy works on gene transfer technology that enhances the immune response of cancer affected patient by destroying tumor cells. In 2017, two CAR-T Cell therapies were approved by the Food and Drug Administration (FDA), one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.
CAR-T Cell market is majorly driven by an increasing number of cancer cases and high demand for effective therapy in this area. The increasing number of products in the clinical pipeline under development would act as a growth catalyst for the global market. The ability of therapy to treat recurrent cancers with high efficiency is also contributing significantly to the market growth.
CD19 is the most targeted antigen for a limited range of blood cancers. Hematological cancers indicate a highly competitive therapy segment as compared to solid tumors, in which it is little difficult to identify the antigens and will offer a vast market potential. With the recent launch of CAR-T cell therapies like Kymriah and Yescarta, the market is estimated to witness robust growth in the upcoming years.
The market exhibit huge potential for companies engaged in developing, manufacturing of CAR T cell therapies for cancer treatment. Upcoming novel products and technologies and the presence of big players in the market will result in intense competition in future.
The report “Global CAR-T Cell Market: Industry Analysis & Outlook (2019-2023)” by Koncept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States, Europe, and Japan region along with the global market. The report profiles the key players of the market including Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.